metronidazole 0.01 MG/MG Topical Gel [MetroGel]

Verify with CMS →

metronidazole

RxCUI: 605730

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0%
Plan Coverage
2
Plans Covering
T1
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for metronidazole 0.01 MG/MG Topical Gel [MetroGel]

Per the CMS 2026 Part D formulary file, metronidazole 0.01 MG/MG Topical Gel [MetroGel] (RxNorm concept RXCUI 605730, generic name metronidazole) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to metronidazole 0.01 MG/MG Topical Gel [MetroGel] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,528,785 Part D beneficiaries filled metronidazole 0.01 MG/MG Topical Gel [MetroGel] in 2023, with total plan-and-beneficiary spending of $70,489,119 and an average per-beneficiary annual cost of $46.11. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry metronidazole 0.01 MG/MG Topical Gel [MetroGel] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
1,528,785
Total spending
$70,489,119
Avg per beneficiary
$46.11

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering metronidazole 0.01 MG/MG Topical Gel [MetroGel]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 No $34.50 NY

Frequently Asked Questions

Is metronidazole 0.01 MG/MG Topical Gel [MetroGel] covered by Medicare Part D?

Yes, metronidazole 0.01 MG/MG Topical Gel [MetroGel] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is metronidazole 0.01 MG/MG Topical Gel [MetroGel] on Medicare Part D plans?

metronidazole 0.01 MG/MG Topical Gel [MetroGel] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does metronidazole 0.01 MG/MG Topical Gel [MetroGel] require prior authorization?

0% of Part D formularies require prior authorization for metronidazole 0.01 MG/MG Topical Gel [MetroGel]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on metronidazole 0.01 MG/MG Topical Gel [MetroGel]?

In 2023, total Medicare Part D spending on metronidazole 0.01 MG/MG Topical Gel [MetroGel] was $70,489,119, covering 1,528,785 beneficiaries. The average spend per beneficiary was $46.11.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial